Daily news email for August 24, 2012 | Click here for updated news
SourceSolution News
We want to hear from you! Click here let us know how we can make this news email better.
Manage projects more efficiently. Try PlanIt free for 15 days.
Create quality questionnaires and RFPs more quickly, weight responses and manage suppliers.
Discounted advertising rates on www.sourcesolution.com for all BIOCOM members starting at $100/month
Use PlanIt as your next deal room! Click here to learn more.
|
b3c newswire
ZZ Biotech Initiates Phase 1 Study with 3K3A-APC for the Treatment of Acute Ischemic Stroke
AiCuris Promising Drugs Against Herpes Simplex (AIC316) and Human Cytomegalovirus (Letermovir, ...
CEVEC Licenses its Proprietary Human Cell Lines to Paragon Bioservices, Inc.
Cambridge Research Biochemicals Signs Deal with LI-COR Biosciences for Infrared Dye Labelled ...
2. Laupheimer Zelltage Attracts Top Scientists to Discuss Recent Advances in Biomanufacturing
|
BioSpace
Putting Feelings Into Words Can Help Us Cope With Scary Situations, University of California, Los Angeles (UCLA) Study
Optimal Length of Mitochondria is Essential to Preventing Alzheimer's, Massachusetts General Hospital Study
Cat Owners at No Risk of Brain Cancer, and Oxford University Study
Merck & Co., Inc. Licensing HIV Experimental Drugs
Histone-Modifying Proteins, Not Histones, Remain Associated With DNA Through Replication, Thomas Jefferson University Study
|
Biotechnology - Moreover
Analysis of Relative Performance in the Biotechnology Industry for Shares of Incyte (INCY, ONXX, ALKS, SPPI, MITI)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CPHD, IMGN, HGSI, SGEN, RIGL)
NIH Translational Center Should Raise All Boats, BIO Says
Immunogen, inc. reports second quarter fiscal year 2012 financial results and provides quarterly update
Biotechnology to be 21st-century industry: Life Tech CEO
|
Burrill Report
The September 2012 Issue of The Burrill Report
The September 2012 Issue of The Burrill Report
Elan to Shed Drug Discovery Unit
RNA Therapeutics in the Dealmaking Spotlight
Pfizer's Animal Health Unit Zoetis Files IPO
|
CenterWatch - Clinical Trials
Sanofi's $20 billion Genzyme buy could fuel a big pharma-biotechnology acquisition trend
New Quintiles initiative saves investigative sites the time, and cost, of patient recruitment advertising
Technology companies adapt interactive video concepts for clinical trial informed consent
CRI buys Lifetree, combining investigative sites on both coasts and across all trial phases
New $1b NIH center will tackle early-stage drug development to ease industry risk of failure
|
Clinical Trials - Business Wire
Research and Markets: Leprosy Global Clinical Trials Review, H2, 2012
BioReference Laboratories, Inc. Announces Earnings Date for Third Quarter Fiscal Year 2012
Research and Markets: Alpha - Antitrypsin Deficiency Global Clinical Trials Review, H2, 2012
Research and Markets: Uterine Fibroids Global Clinical Trials Review, H2, 2012
Research and Markets: Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2012
|
Clinical Trials - PR Newswire
Eli Lilly and Company Announces Top-Line Results on Solanezumab Phase 3 Clinical Trials in Patients with Alzheimer's Disease
Biodesix Announces New VeriStrat® Data to be Presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology
Star Scientific's Rock Creek Subsidiary Enrolls First Alzheimer's Study Patient at Roskamp Institute
Elderly Kids: Alarming Number of US Children Affected by Adult-Onset Diseases
Canary Foundation announces $8.5 million in gifts to advance vital cancer early detection studies
|
CNN Top Stories
Guard gave chase, witnesses say
Witnesses recount chaos
E-mail threat on Obama spurs arrest
Norwegian killer sentenced to 21 years
Lochte's fame getting him 'digits'
|
New York Times- Pharmaceuticals
Bristol-Myers Ends Work on Hepatitis C Drug
Clues to Fighting Cancer Are Found in the Genes of Yeast
Get Antibiotics Off the Farm
Amgen, Citing Weak Results, Halts Study of a Cancer Drug
Pfizer Animal Health Unit Files for I.P.O.
|
OnBioVC
Stemgent, Inc.: Series C $6.3M
Genalyte, Inc.: Series A $11.8M
Relievant Medsystems, Inc.: Series D $30M
ImaginAb, Inc.: Series A $12.5M
BiO2 Medical, Inc.: Series B $13.7M
|
Outsourcing-Pharma
Changes to EU clinical trial laws will mean fairer playing field, says Clinipace
Wockhardt targets CMO space for diversification
Overhaul of EU health systems good opportunity for outcomes data providers, says Quintiles
Home visits = regulatory thumbs up ResearchNurses.co thinks so
Home visits are the key to patient retention, says ResearchNurses.co
|
Sports News - ESPN
New Big East boss came to job late in process
Howard football bans 14 players for 1-3 games
S. Carolina's Shaw leaves practice to rest back
Penn State puts blue ribbon on back of helmets
Ohio State reinstates linebacker Klein to team
|
Xconomy Life Sciences
CIMIT, Best Doctors, Inspiration Biopharma, & More Boston Life Sciences Newsmakers
Qualcomm Acquires Israeli Company with Small Cellular Technology
San Diego Life Sciences Roundup: Regulus IPO, Fate Funding, & More
EnVivo Forges Ahead With Alzheimer's Drug
In a Requiem for Helix Wind, Critics Come to Bury More Than Praise
|
Yahoo Biotech News
Slow, costly process stymies generic biotech drugs
(Reuters)
Analysis: Slow, costly process stymies generic biotech drugs
(Reuters)
Waves Break Coral Embryo into Identical Twins
(LiveScience.com)
Autoinjector Version of MS Drug Approved
(HealthDay)
Fake Avastin had salt, starch, chemicals: Roche
(Reuters)
|
